Kintegral Advisory’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.2M | Hold |
15,208
| – | – | 1.48% | 11 |
|
|
2026
Q1 | $14M | Sell |
15,208
-674
| -4% | -$683K | 1.33% | 10 |
|
|
2025
Q4 | $17.1M | Sell |
15,882
-435
| -3% | -$416K | 1.45% | 7 |
|
|
2025
Q3 | $12.4M | Sell |
16,317
-73
| -0.4% | -$54.3K | 1.06% | 18 |
|
|
2025
Q2 | $12.8M | Sell |
16,390
-25
| -0.2% | -$19.4K | 1.16% | 15 |
|
|
2025
Q1 | $13.6M | Sell |
16,415
-56
| -0.3% | -$46.6K | 1.37% | 9 |
|
|
2024
Q4 | $12.7M | Sell |
16,471
-768
| -4% | -$636K | 1.2% | 11 |
|
|
2024
Q3 | $15.3M | Sell |
17,239
-226
| -1% | -$203K | 1.4% | 6 |
|
|
2024
Q2 | $15.8M | Buy |
17,465
+1,570
| +10% | +$1.26M | 1.52% | 7 |
|
|
2024
Q1 | $12.4M | Sell |
15,895
-50
| -0.3% | -$35.6K | 1.24% | 12 |
|
|
2023
Q4 | $9.29M | Sell |
15,945
-102
| -0.6% | -$59.5K | 1.03% | 17 |
|
|
2023
Q3 | $8.62M | Sell |
16,047
-10
| -0.1% | -$5.15K | 1.06% | 16 |
|
|
2023
Q2 | $7.53M | Hold |
16,057
| – | – | 0.89% | 22 |
|
|
2023
Q1 | $5.51M | Sell |
16,057
-863
| -5% | -$291K | 0.71% | 36 |
|
|
2022
Q4 | $6.19M | Buy |
16,920
+5,900
| +54% | +$2.09M | 0.82% | 31 |
|
|
2022
Q3 | $3.56M | Hold |
11,020
| – | – | 0.49% | 52 |
|
|
2022
Q2 | $3.57M | Buy |
11,020
+233
| +2% | +$69.9K | 0.46% | 55 |
|
|
2022
Q1 | $3.09M | Buy |
10,787
+241
| +2% | +$62K | 0.34% | 77 |
|
|
2021
Q4 | $2.91M | Hold |
10,546
| – | – | 0.3% | 84 |
|
|
2021
Q3 | $2.44M | Hold |
10,546
| – | – | 0.29% | 83 |
|
|
2021
Q2 | $2.42M | Hold |
10,546
| – | – | 0.29% | 85 |
|
|
2021
Q1 | $1.97M | Hold |
10,546
| – | – | 0.25% | 99 |
|
|
2020
Q4 | $1.78M | Hold |
10,546
| – | – | 0.24% | 103 |
|
|
2020
Q3 | $1.56M | Sell |
10,546
-339
| -3% | -$52.5K | 0.24% | 103 |
|
|
2020
Q2 | $1.79M | Hold |
10,885
| – | – | 0.29% | 84 |
|
|
2020
Q1 | $1.51M | Buy |
10,885
+1,218
| +13% | +$167K | 0.29% | 88 |
|
|
2019
Q4 | $1.27M | Hold |
9,667
| – | – | 0.23% | 115 |
|
|
2019
Q3 | $1.08M | Hold |
9,667
| – | – | 0.22% | 126 |
|
|
2019
Q2 | $1.07M | Hold |
9,667
| – | – | 0.22% | 123 |
|
|
2019
Q1 | $1.25M | Sell |
9,667
-409
| -4% | -$49.7K | 0.26% | 108 |
|
|
2018
Q4 | $1.17M | Buy |
+10,076
| New | +$1.13M | 0.35% | 74 |
|
Other funds holding LLY
Kintegral Advisory's LLY Position: Q2 2026 in Review
Kintegral Advisory held its Eli Lilly (LLY) position steady in Q2 2026 at 15,208 shares worth $18.2M. The position accounts for 1.48% of the portfolio, ranked #11.
Kintegral Advisory first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Kintegral Advisory held 15,208 shares of Eli Lilly worth $18.2M as of Q2 2026.
- Kintegral Advisory left its Eli Lilly share count unchanged in Q2 2026.
- Eli Lilly made up 1.48% of Kintegral Advisory's portfolio in Q2 2026, its #11 holding.
- Kintegral Advisory first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.